Persona
AGHEMO Alessio Michele Goffredo
Docenti di ruolo di Ia fascia
Course Catalogue:
Description
CURRICULUM VITAE
Nome e Cognome: Alessio Michele Goffredo Aghemo
Nascita: 14/2/1975 Milano
Cittadinanza: Italiana
Residenza: Milano
Codice fiscale: GHMLSM75B14F205A
Indirizzo del luogo di lavoro:
Departimento di Scienze Biomediche
Humanitas University
UO Medicina Interna ed Epatologia
Humanitas Research Hospital
Via Manzoni 56, 20089, Rozzano (MI)
E-mail: alessio.aghemo@hunimed.eu
alessio.aghemo@gmail.com
CORSO DEGLI STUDI ED INCARICHI PROFESSIONALI
1994 Maturita' Scientifica, Liceo Gonzaga, Via Vitruvio 41 Milano
2001 Laurea in Medicina e Chirurgia, votazione 110/110 lode, Universita' degli Studi di Milano,
2001-2005 Specializzazione in Gastroenterologia ed Endoscopia digestiva votazione 70/70 lode, Università degli Studi di Milano
2005-2008 Dottorato di Ricerca in Gastroenterologia, Universita' degli Studi di Milano
2006-2007 Borsa di Ricerca, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
2007-oggi Dirigente Medico di I livello, UO di Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano.
2008-oggi Professore a contratto della Scuola di Specializzazione in Gastroenterologia Digestiva ed Endoscopia dell’Università degli Studi di Milano
2008-oggi Docente del corso di Laurea Magistrale in Medicina e Chrirurgia della facoltà di Medicina e Chirurgia dell’Università degli Studi di Milano
2011-2013 Docente del Corso di Laurea in “Tecniche di Radiologia Medica, per immagini e radioterapia” dell’Università degli Studi di Milano
2013 Abilitazione scientifica nazionale a Professore Associato di Gastroenterologia
2014-2017 Indennità Professionale di alta Specializzazione in Epatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano
2017-2021 Professore Associato di Gastroenterologia, Humanitas University, Rozzano Italia
2017-oggi Responsabile UO Medicina generale ed Epatologia, Humanitas Research Hospital, Rozzano Italia
2021-oggi Professore Ordinario di Gastroenterologia, Humanitas University, Rozzano Italia
CONOSCENZE LINGUISTICHE
Inglese Scritto e Parlato: Ottimo
Francese: Scritto Buono, Parlato Ottimo
ATTIVITA’ DIDATTICA E SCIENTIFICA
Attività didattica
Anno Accademico 2007-2008
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Anno Accademico 2008-2009
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Anno Accademico 2009-2010
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Anno Accademico 2010-2011
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Anno Accademico 2011-2012
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Tecniche di radiologia medica, per immagini e radioterapia, corso di Malattie infettive dell’Università degli Studi di Milano.
Anno Accademico 2012-2013
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Tecniche di radiologia medica, per immagini e radioterapia, corso di Malattie infettive dell’Università degli Studi di Milano.
Anno Accademico 2014-2015
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Anno Accademico 2015-2016
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Anno Accademico 2016-2017
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Tutor per le attività professionalizzanti per gli studenti di corso di Laurea in Medicina e chirurgia dell’Università degli Studi di Milano.
Anno Accademico 2017-2021
Professore Associato di Gastroenterologia presso la Humanitas University
Anno Accademico 2021-oggi
Professore Ordinario di Gastroenterologia presso la Humanitas University
Attività scientifica
Dal 2005 al 2017 ha svolto la sua attività scientifica presso i laboratori della U.O. di Gastroenterologia I della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, di Milano.
E’ stato fino al 2017 responsabile della sezione HCV dei laboratori di ricerca della U.O. Gastroenterologia ed Epatologia
E’ stato visiting fellow presso la Duke University nel 2010, sotto la diezione del Professore Andrew J. Muir.
I principali temi di ricerca sono stati:
1) Ottimizzazione della efficacia e tollerabilità della terapia antivirale contro HCV
2) Impatto dei polimorfismi genetici sulla storia naturale dell’epatite cronica HCV e sull’efficacia terapeutica dei farmaci antivirali
3) Caratterizzazione delle resistenze virali a farmaci anti-HCV ad azione diretta e loro impatto sull’efficacia dei farmaci stessi
Ha partecipato in qualità di esperto alla stesura delle Linee Guida Europee 2013-2014-2015-2016 (EASL) ed Italiane (AISF) sul Trattamento dell’Epatite Cronica C.
E’ componente del gruppo di esperti Europei che sta preparando le linee guida EASL per l’epatite cronica C del 2017.
E’ socio dell’European Association for the Study of the Liver (EASL), dell’ American Association for the Study of the Liver (AASLD), dell’Associazione Italiana Studio Fegato (AISF) e della Società Italiana di Gastroenterologia (SIGE).
E’ stato Associate Editor di Liver International dal 2013 al 2019.
Dal 2019 ad oggi è Co Editor in Chief di Liver International
E’ membro dell’editorial board delle seguenti riviste: Journal of Hepatology, Gut.
È stato Revisore delle seguenti riviste scientifiche internazionali: Hepatology, Gastroenterology, Lancet Infectious diseases, Gut, Journal of Hepatology, Annals of Internal Medicine, Journal of Viral Hepatitis, Lancet Gastroenterology and Hepatology, Liver International, Journal of Medical Virology, BMC Gastroenterology, Clinical Gastroenterology and Hepatology.
E’ autore di 280 pubblicazioni su riviste peer-reviewed (Impact Factor totale >2000, H-Index 45 secondo Scopus, H-Index 50 secondo Google Scholar)
Attività di Cordinamento e Finanziamenti
Dal 2013 al 2016 è stato scientific member del governing board dell’European Association for the Study of the Liver (EASL).
Dal 2016 è member del scientific comitee della associazione Europea di Gastroenterologia (UEG)
É membro della commissione AISF per i farmaci antivirali diretti contro HCV (2012-oggi). Dal 2016 è cordinatore della stessa.
Esperto AIFA/EMEA per la malattie del fegato dal 2008
Membro del Comitato Esecutivo della Rete Regionale HCV, determinata da Regione Lombardia in data 28 Settembre 2015 (determina 7826).
Dal 2016 fino al 2019 è membro del comitato scientifico del Centro Universitario A.M e A. Migliavacca per lo Studio e la Cura delle malatie del fegato dell’Università degli studi di Milano
Vincitore del Progetto Fellowship Program GILEAD Titolo del progetto: Creazione di un punteggio per identificare le persone ad alto rischio di sviluppo di infezione da virus dell’epatite C dopo esposizione professionale per identificare I candidati ideali a profilassi antivirale post-esposizione. Finanziamento 15.000 Euro
Vincitore del Progetto di Ricerca Giovani Ricercatori del Ministero della Salute Bando 2011 come membro del team di ricerca di centro affiliato. Titolo: Effect of Proteasome and VEGF receptor inhibitors on NKG2D ligand expression on hepatocellular carcinoma cells: implications for immunotherapy of liver cancer. Finanziato con 62.000 Euro.
ATTIVITA’ CLINICA ASSISTENZIALE
- Dal 1998 al 2001, ha svolto attività di Medico Interno c/o il reparto di Degenza e l’ambulatorio di epatologia della Unità di Gatroenterologia 1, IRCCS Ospedale Maggiore Policlinico, Milano.
- Dal 2001 al 2005 ha svolto attività clinica ed endoscopica presso le unità di Gatroenterologia I e III della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2006 al 2017 ha svolto attività clinico assistenziale presso la U.O di Gastroenterologia I della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2007 al 2017 è stato Dirigente medico di 1° Livello presso la U.O di Gastroenterologia I della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano
- Nel 2009 è stato Medico Responsabile del Reparto Degenza, UO di Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2009 al 2017 è consulente epatologo della divisione del centro emofilia e trombosi Bianchi Bonomi della Divisione di Medicina Interna, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2008 al 2017 è consulente epatologo dell’Ospedale Ortopedico Gaetano Pini di Milano
- Dal 2010 al 2017 è referente per le attività ambulatoriali della U.O di Gastroenterologia ed Epatologia della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- Dal 2014 al 2017 ha l’Indennità Professionale di alta Specializzazione (IPS) in Epatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano
- Dal 2017 ad oggi è Capo sezione presso la UO Medicina generale ed Epatologia, Humanitas Research Hospital, Rozzano Italia
ARTICOLI ORIGINALI
1. Viganò M, Visentin S, Aghemo A, Rumi M.G, Ronchi G. Ultrasound features of liver surface nodularity predict severe fibrosis in chronic hepatitis C. Radiology 2005;234(2):641
2. Monti V, Aghemo A, Rumi MG, Donato F, Del Ninno E, Colombo M. Prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C and liver-kidney microsomal antibodies. Antiviral Therapy 2005;10(6):715-720.
3. Rumi M, D’Ambrosio R, Aghemo A. The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology 2006 Apr;44(4):825.
4. Aghemo A, Rumi MG, Soffredini R, D’Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antiviral Therapy 2006; 11 (6): 797-802.
5. Rumi MG, Aghemo A, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Therapy 2007;12(7):1033-40
6. Viganò M, Aghemo A, Iavarone M. The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis. Gastroenterology 2007;133(6):2076.
7. Taliani G, Rucci P, Biliotti E, Cirrincione L, Aghemo A, Alberti A, Almasio PL, Bartolozzi D, Caporaso N, Coppola R, Chiaramonte M, Floreani A, Gaeta GB, Persico M, Secchi G, Versace I, Zacharia S, Mele A. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. J Viral Hepat. 2007;14(12):875-82.
8. Aghemo A, Rumi MG, Colombo M. Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? J Viral Hepat. 2008;15(6):471
9. Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur J Intern Med. 2008;19(5):370-1.
10. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, Andreone P, Stanzione M, Mazzella G, Saracco G, Del Poggio P, Bruno S; on behalf of Italian Association of the Study of the Liver Disease (AISF). Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. Am J Gastroenterol. 2008;103(8):1966-72.
11. Aghemo A, D’Ambrosio R, Rumi MG, Colombo M. Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C: more questions than answers. Hepatitis Monthly. 2008;8(4):304-309
12. Aghemo A, Colombo M. Cirrhosis Regression in Chronic Hepatitis c: an old tale with a new ending. Gastroenterology. 2009;136(3):1114-6.
13. Aghemo A, Rumi MG, Prati GM, Colombo M. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more? Hepatology. 2009;49(2).
14. Martinelli I, Primignani M, Aghemo A, Reati R, Bucciarelli P, Fabris F, Battaglioli T, Dell'era A, Mannucci PM. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol. 2009 May;50(5):916-22
15. Tripodi A, Chantarangkul V, Primignani M, Dell’Era A, Clerici M, Iannuzzi F, Aghemo A, Cazzaniga M, Salerno F, Mannucci PM. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement INRliver for the calculation of the MELD score. J Hepatol. 2009;51(2):288-95.
16. Aghemo A, Rumi MG, Monico S, Prati GM, D’Ambrosio R, Donato MF, Colombo M. The pattern of peginterferon alfa-2b ribavirin treatment failure in cirrhotics depends on hepatitis C virus genotype. Antivir Ther. 2009;14(4):577-84
17. M Viganò§, A Aghemo§, M Iavarone, MG Rumi, F Agnelli, P Lampertico, MF Donato and M .Colombo. The course of inactive hepatitis B in hepatitis C co-infected patients treated with interferon and ribavirin. Antiviral Therapy 2009 14(6):789-96.
18. Aghemo A, Colombo M. Treatment of nonresponder patients with chronic hepatitis C: to repeat or not to repeat? That is the question. Gastroenterology. 2009 Oct;137(4):1521-4;
19. De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C.J Hepatol. 2009 Nov;51(5):964-6.
20. Mancuso ME, Rumi MG, Aghemo A, Santagostino E, Puoti M, Coppola A, Colombo M, Mannucci PM. HCV/HIV co-infection in hemophiliacs: high rates of sustained virological response to pegylated interferon and ribavirin therapy. J Thromb Haemost. 2009;7(12):1997-2005
21. Aghemo A, Rumi MG, Colombo M. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther. 2009 Oct;7(8):925-35
22. Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV Therapy. Viruses 2009, 1(3), 484-509
23. Rumi M, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M. Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology. 2010;138(1):108-15
24. Aghemo A, Colombo M. Peginterferon Alfa-2B Versus Peginterferon Alfa-2A With Ribavirin for the Treatment of Chronic Hepatitis C: The Pursuit of an Ideal. Gastroenterology. 2010;138(1):386-9
25. Aghemo A, Colombo M. Genetic Variation in Interleukin-28B Predicts Hepatitis C Treatment-Induced Viral Clearance in Genotype 1 Patients: The Dawn of a New Era? Gastroenterology. 2010;138(7):2546-9
26. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell'Era A, Iannuzzi F, Aghemo A, Mannucci PM. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology. 2010;52(1):249-55.
27. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2010;7(9):485-94.
28. Aghemo A, Colombo M. Telaprevir for Hepatitis C Retreatment: An Open Door on a Long and Winding Road. Gastroenterology. 2010 Aug 20. [Epub ahead of print]
29. Aghemo A, Rumi MG, De Nicola S, Colombo M. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. Hepatology. 2010;52(3):1170-1.
30. Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, Ronchi G, Biondetti P, Roncalli M, Colombo M. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology. 2010;52(5):1723-30.
31. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32(13):2117-38.
32. Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A, Mannucci PM. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med. 2011 Feb 5.
33. Vezali E, Aghemo A, Colombo M Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther. 2011;11(3):301-13.
34. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53(3):791-9.
35. Aghemo A, Colombo M. A Rapid Point-of-Care Test for the Diagnosis of HCV Infection: Tipping the Balance to Screening Extension Beyond High Risk Populations? Gastroenterology. 2011;140(4):1347-9
36. Aghemo A, Rumi MG, Monico S, Banderali M, Russo A, Ottaviani F, Vigano M, D'Ambrosio R, Colombo M. Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepat Mon. 2011 Nov;11(11):918-24.
37. Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol. 2011 Mar 22. [Epub ahead of print] IF 318
38. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011 Oct;54(4):1127-34. doi: 10.1002/hep.24503.
39. Prati GM, Aghemo A, Rumi MG, D'Ambrosio R, De Nicola S, Donato MF, Degasperi E, Colombo M. Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol. 2012 Feb;56(2):341-7.
40. Aghemo A, Colombo M. Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. J Hepatol. 2012;56(1):276-8.
41. D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'Era A, Lampertico P, Donato MF, De Nicola S, Prati GM, de Franchis R, Colombo M. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16(5):677-84.
42. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012;55(2):336-42.
43. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12(2):193-207.
44. Valenti L, Aghemo A, Stättermayer AF. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol. 2012 May;56(5):1209-10.
45. Degasperi E, Aghemo A. Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:3-6.
46. Rumi M, Aghemo A, Prati GM. Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:37-41.
47. D'Ambrosio R, Aghemo A, Grazia Rumi M, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients. Hepatology. 2012 Jan 23. doi: 10.1002/hep.25606
48. Donato MF, Galmozzi E, Rigamonti C, Aghemo A. Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. J Hepatol. 2012 Jan 28. [Epub ahead of print]
49. Aghemo A, Prati GM, Colombo M. Reply to: "The "pegylated" story continues - Perhaps because both ends (α2a and α2b) are true?" J Hepatol. 2012 Mar 3. [Epub ahead of print]
50. Aghemo A, Colombo M. Interferon-Free Oral Therapy for Hepatitis C: "Faraway, so Close!". Gastroenterology. 2012;142(5):1253-4.
51. Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther. 2012;35(12):1434-42
52. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. Hepatology. 2012 56(5):1681-7
53. Aghemo A.Understanding the Role of PNPLA3 Genetic Variants in Patients with Chronic Hepatitis C Infection. Dig Dis Sci. 2012 Jun 27. [Epub ahead of print] No abstract available.
54. Aghemo A, Lampertico P, Colombo M. Assessing Long-Term Treatment Efficacy in Chronic Hepatitis B and C: Between Evidence and Common Sense. J Hepatol. 2012 Jun 27. [Epub ahead of print]
55. Galmozzi E, Aghemo A, Colombo M. Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin? Med Hypotheses. 2012;79(4):471-3
56. D'Ambrosio R, Aghemo A.Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon. 2012;12(6):361-8
57. D'Ambrosio R, Aghemo A, Colombo M. Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. Biologics. 2012;6:363-70.
58. Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon. 2012;12(6):411-4
59. Aghemo A, Colombo M. Insulin Resistance and Response to Telaprevir Plus Pegylated Interferon and Ribavirin: a Requiem For The Homa Score? Gastroenterology. 2012;143(6):1685-7
60. Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. Dig Liver Dis. 2013;45(1):1-7.
61. Galmozzi E, Aghemo A, Colombo M. Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. Hepatology. 2013 May;57(5):2087.
62. Galmozzi E, De Nicola S, Aghemo A, Colombo M. Is there need for more than one IL28B SNP in Hepatitis C clinical practice? Hepatology 2013. Jan;57(1):416.
63. Iavarone M, Manini MA, Sangiovanni A, Fraquelli M, Forzenigo LV, Di Tommaso L, Aghemo A, Roncalli M, Ronchi G, Colombo M. Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Dig Liver Dis. 2013;45(1):43-9
64. Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol. 2013 Jan;35(1):111-20
65. Lotta LA, Degasperi E, Aghemo A, Ferrari B, Peyvandi F, Colombo M. Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. Transfus Med. 2013;23(1):66-8.
66. Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P. Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. J Virol Methods. 2013;187(2):271-3.
67. Grassi E, Aghemo A. How to optimize HCV therapy in genotype 2 patients. Liver Int. 2013;33 Suppl 1:35-40.
68. Dell'Osso B, Prati G, Palazzo MC, Rumi MG, Cavallaro F, Aghemo A, Colombo M, Altamura AC. Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. J Interferon Cytokine Res. 2013;33(1):9-14
69. Aghemo A, De Francesco R New horizons in Hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58(1):428-38..
70. Oliviero B, Mele D, Degasperi E, Aghemo A, Cremonesi E, Grazia Rumi M, Tinelli C, Varchetta S, Mantovani S, Colombo M, Mondelli MU. Natural Killer Cell Dynamic Profile Is Associated with Treatment Outcome in Patients with Chronic HCV Infection. J Hepatol. 2013;59(1):38-44
71. D'Ambrosio R, Aghemo A, Fraquelli M, Grazia Rumi M, Francesca Donato M, Paradis V, Bedossa P, Colombo M. The Diagnostic Accuracy of Fibroscan for Cirrhosis is Influenced by Liver Morphometry in HCV Patients with a Sustained Virological Response. J Hepatol. 2013;59(2):251-6
72. Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol. 2013 Mar 7;19(9):1359-71.
73. Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, Grassi E, Colombo M. Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. Biomed Res Int. 2013;2013:580796.
74. Degasperi E, Viganò M, Aghemo A, Lampertico P, Colombo M. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther. 2013;11(5):459-74
75. Aghemo A, Colombo M. Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. Gastroenterology. 2013;145(1):247-9.
76. Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013 Jul 3. doi: 10.1038/ki.2013.264.
77. Aghemo A, Colombo M. Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut. 2013 Aug 6. doi: 10.1136/gutjnl-2013-305115
78. Aghemo A, Lampertico P. Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. Aliment Pharmacol Ther. 2013 Sep;38(5):553-4
79. De Nicola S, Aghemo A, Campise MR, D'Ambrosio R, Rumi MG, Messa P, Colombo M. Telaprevir in a patient with chronic hepatitis C and Cryoglobulinemic Glomerulonephritis. Antivir Ther. 2013 Sep 6. doi: 10.3851/IMP2684.
80. Dell'Era A, Iannuzzi F, Fabris FM, Fontana P, Reati R, Grillo P, Aghemo A, de Franchis R, Primignani M. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig Liver Dis. 2014 Feb;46(2):152-6
81. Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2014 Jan;46(1):18-24.
82. Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D'Ambrosio R, Muir AJ, Colombo M. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat. 2013 Dec;20(12):858-66
83. Fabrizi F, Aghemo A, Moroni G, Passerini P, D'Ambrosio R, Martin P, Messa P. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review). Dig Dis Sci. 2014 Mar;59(3):691-5.
84. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420
85. Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res. 2013;37(6):588-601.
86. Fraquelli M, Giunta M, Pozzi R, Rigamonti C, Della Valle S, Massironi S, Conti CB, Aghemo A, Ronchi G, Iurlo A, Primignani M, Conte D, Colombo M. Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis. J Viral Hepat. 2014 Feb;21(2):90-8
87. Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol. 2014 Jan 11. pii: S0168-8278(14)00013-0. doi: 10.1016/j.jhep.2014.01.002
88. Galmozzi E, Aghemo A. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. J Clin Virol. 2014 Apr;59(4):274-5. doi: 10.1016/j.jcv.2014.01.006.
89. Mancuso ME, Linari S, Aghemo A, Bartolozzi D, Santagostino E, Rumi MG, Fognani E, Fasulo MR, Gragnani L, Bruno R, Morfini M, Zignego AL, Colombo M. Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thromb Haemost. 2014 Feb 13;111(6).
90. Degasperi E, Valenti L, Aghemo A, De Francesco R, Rumi M, Soffredini R, Donnici L, Cheroni C, Fargion S, Zanoni V, Orsi E, Colombo M. Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. Antivir Ther. 2014 Feb 12. doi: 10.3851/IMP2743
91. Fabrizi F, Aghemo A, Fogazzi GB, Moroni G, Passerini P, D'Ambrosio R, Messa P. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38(1):52-60. doi: 10.1159/000355753
92. Aghemo A, Colombo M. Hepatitis C genotype 3: a tough match for interferon-free regimens. Gastroenterology. 2014 Apr;146(4):1125-7
93. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420
94. De Nicola S, Aghemo A. Second wave Anti-HCV Protease Inhibitors: Too little too late? Liver Int. 2014 Mar 20. doi: 10.1111/liv.12543
95. Galmozzi E, Facchetti F, Perbellini R, Aghemo A. High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. Clin Microbiol Infect. 2014 Apr 11. doi: 10.1111/1469-0691.12637. [Epub ahead of print]
96. Ronzoni L, Aghemo A, Rumi MG, Prati G, Colancecco A, Porretti L, Monico S, Colombo M, Cappellini MD. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat. 2014 Jun;21(6):416-23
97. Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M. Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. PLoS One. 2014 Apr 23;9(4):e95881.
98. D'Ambrosio R, Aghemo A, De Francesco R, Rumi MG, Galmozzi E, De Nicola S, Cheroni C, Clark PJ, Ronchi G, Lampertico P, Colombo M. The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci. 2014 Apr 25;15(5):7213-24
99. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med. 2014 Apr 29;6:25-33
100. Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. Dig Liver Dis. 2014 Sep;46(9):818-25.
101. Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, Torresani E, Ronchi M, Garlaschi MC, Ramondetta M, Colombo M. Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients. J Viral Hepat. 2014 Jul 14. doi: 10.1111/jvh.12281
102. Donato MF, Monico S, Malinverno F, Aghemo A, Maggioni M, Reggiani P, Colombo M. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int. 2014 Jul 29. doi: 10.1111/liv.12646.
103. De Nicola S, Dongiovanni P, Aghemo A, Cheroni C, D'Ambrosio R, Pedrazzini M, Marabita F, Donnici L, Maggioni M, Fargion S, Colombo M, De Francesco R, Valenti L Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS One. 2014 Aug 29;9(8):e106022
104. Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut. 2014 Sep 5. pii: gutjnl-2014-307958
105. Fabrizi F, D'Ambrosio R, Pallotti F, Berardinelli L, Messa P, Martin P, Aghemo A. Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study. Int J Artif Organs. 2014;37(11):803-8.
106. Aghemo A, Donato MF.Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148(1):13-6.
107. D'Ambrosio R, Aghemo A, Colombo M. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opin Drug Saf. 2015;14(3):473-84
108. Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D'Ambrosio R, Maggioni M, De Francesco R, Fargion S, Berg T, Stickel F, Hampe J, Romeo S, Colombo M, Valenti L. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015 Jul;62(1):111-7. doi: 10.1002/hep.27811. Epub 2015 May 6
109. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21..
110. Romeo S, Aghemo A, Berg T, Stickel F, Valenti L. Reply. Hepatology. 2015 May 16. doi: 10.1002/hep.27901.
111. Manini MA, Sangiovanni A, Martinetti L, Viganò D, La Mura V, Aghemo A, Iavarone M, Crespi S, Nicolini A, Colombo M. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl. 2015 Oct;21(10):1259-69. doi: 10.1002/lt.24196.
112. Aghemo A, Colombo M. Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era? Gastroenterology. 2015 Aug;149(2):500-1. doi: 10.1053/j.gastro.2015.06.035. Epub 2015 Jun 27. No abstract available
113. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.
114. Bruno R, Aghemo A. Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00549-8. doi: 10.1016/j.jhep.2015.05.034. [Epub ahead of print] No abstract available.
115. Grancini V, Trombetta M, Lunati ME, Zimbalatti D, Boselli ML, Gatti S, Donato MF, Resi V, D'Ambrosio R, Aghemo A, Pugliese G, Bonadonna RC, Orsi E. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. J Hepatol. 2015 Aug 20. pii: S0168-8278(15)00553-X. doi: 10.1016/j.jhep.2015.08.011.
116. Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, Sarrazin C. Should HCV-infected patients with debilitating fatigue be prioritized for treatment with interferon-free regimens? J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00619-4. doi: 10.1016/j.jhep.2015.09.004. [Epub ahead of print] No abstract available.
117. Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, Abrignani S, Neddermann P, De Francesco R. Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. PLoS One. 2015 Sep 25;10(9):e0138546. doi: 10.1371/journal.pone.0138546. eCollection 2015.
118. Premoli C, Aghemo A. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants. Minerva Gastroenterol Dietol. 2016 Mar;62(1):76-87.
119. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015 Nov;64(11):1824-33.
120. Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden - volume 3 (editorial). J Viral Hepat. 2015 Dec;22 Suppl 4:1-3
121. Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V, Fischer J, Berg T, Aghemo A, Cheroni C, De Francesco R, Fargion S, Colombo M, Datz C, Stickel F, Valenti L, Romeo S. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology. 2016 Feb;63(2):418-27
122. Paolini D, Lunghi G, Aghemo A, Dionisi M, Colombo M, Torresani E. Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or Triple) Therapy of Hcv Genotype 1 Infection. Value Health. 2015 Nov;18(7):A587
123. Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2015;16(17):2679-88
124. Varchetta S, Mele D, Lombardi A, Oliviero B, Mantovani S, Tinelli C, Spreafico M, Prati D, Ludovisi S, Ferraioli G, Filice C, Aghemo A, Lampertico P, Facchetti F, Bernuzzi F, Invernizzi P, Mondelli MU. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut. 2015 Dec 16. pii: gutjnl-2015-310327. doi: 10.1136/gutjnl-2015-310327
125. Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50
126. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. Int J Drug Policy. 2015 Nov 28. pii: S0955-3959(15)00352-7. doi: 10.1016/j.drugpo.2015.11.010
127. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; l’International Network on Hepatitis among Substance Users (Réseau international sur l’hépatite chez les consommateurs de drogues). Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. Int J Drug Policy. 2015 Nov 28. pii: S0955-3959(15)00351-5. doi: 10.1016/j.drugpo.2015.11.009
128. Aghemo A, Colombo M. No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered? Gastroenterology. 2016 May;150(5):1241-3. doi: 10.1053/j.gastro.2016.03.025
129. Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D'Ambrosio R, Soffredini R, Perbellini R, Lunghi G, Colombo M. Quantification of Core Antigen Monitors Efficacy of Direct-Acting Antiviral Agents in Patients With Chronic Hcv Infection. Clin Gastroenterol Hepatol. 2016 Apr 1. pii: S1542-3565(16)30010-6. doi: 10.1016/j.cgh.2016.03.035. [Epub ahead of print]
130. Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075-1. doi: 10.1016/j.jhep.2016.01.034
131. De Nicola S, Aghemo A. The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. Liver Int. 2016 Jun;36(6):791-3.
132. D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One. 2016 Jun 15;11(6):e0155967. doi: 10.1371/journal.pone.0155967. eCollection 2016.
133. Fraquelli M, Baccarin A, Casazza G, Conti CB, Giunta M, Massironi S, Invernizzi F, Donato MF, Maggioni M, Aghemo A, Conte D, Colombo M. Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease. Aliment Pharmacol Ther. 2016 Jun 30. doi: 10.1111/apt.13711
134. Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. From current status to optimization of HCV treatment: Recommendations from an expert panel. Dig Liver Dis. 2016 Jun 15. pii: S1590-8658(16)30463-7. doi: 10.1016/j.dld.2016.06.004
135. Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia S, Cacciola I, Burroughs AK, Manini MA, La Mura V, Angeli P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, Arghittu M; AISF Investigators. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int. 2016 Jul 1. doi: 10.1111/liv.13195.
136. D'Ambrosio R, Aghemo A, Rossetti V, Carrinola R, Colombo M. Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver Int. 2016 Jul 18. doi: 10.1111/liv.13203
137. Aghemo A, De Nicola S. Chronic hepatitis C: standard of care and perspective. Recenti Prog Med. 2016;107(7):349-54
138. Aghemo A, Buti M. Hepatitis C Therapy: Game Over! Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131-9. doi: 10.1053/j.gastro.2016.09.034
139. Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1373-1383.
140. Colli A, Fraquelli M, Prati D, Riva A, Berzuini A, Conte D, Aghemo A, Colombo M, Casazza G. Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. PLoS One. 2016 Oct 10;11(10):e0164452. doi: 10.1371/journal.pone.0164452.
141. Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, Massetto B, Brainard DM, McHutchison JG, Bourlière M, Peck-Radosavljevic M, Manns M, Pol S. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Ann Intern Med. 2016 Nov 15. doi: 10.7326/M16-1205
142. Tripodi A, D'Ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int. 2017 Jan 27. doi: 10.1111/liv.13374
143. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Jan 20. doi: 10.1111/liv.13327.
144. Aghemo A, Bruno R, Colombo M, Medagli M, Puoti M, Rizzardini G, Fagiuoli S; Lombardia Hepatitis Network. Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):17-19.
145. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20
146. Tripodi A, D'Ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int. 2017 Sep;37(9):1295-1303. doi: 10.1111/liv.13374. Epub 2017 Feb 23
147. Aghemo A, Colombo M. Response-Guided Duration of Direct Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future? Gastroenterology. 2017 Apr;152(5):1238-1239. doi: 10.1053/j.gastro.2017.02.022. Epub 2017 Feb 28. No abstract available.
148. Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K, Piratvisuth T, Shah S, Shiffman ML, Tacke F, Tan SS, Tanwandee T, Win KM, Yurdaydin C. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. doi: 10.1016/S2468-1253(16)30080-2. Epub 2016 Dec 10. Review
149. Invernizzi F, Aghemo A. Treatment of chronic hepatitis C: can complexity pave the way towards elimination? Lancet Gastroenterol Hepatol. 2017 Jul;2(7):465-466. doi: 10.1016/S2468-1253(17)30085-7. Epub 2017 Apr 14. No abstract available
150. Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, Cabibbo G, Rossi S, Calvaruso V, Aghemo A, Giacomelli L, Craxì A, Colombo M, Maisonneuve P. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int. 2017 Apr 18. doi: 10.1111/liv.13452. [Epub ahead of print]
151. D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017 Jun;24:31-37. doi: 10.1016/j.coviro.2017.03.017. Epub 2017 Apr 15. Review.
152. Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis. 2017 Jul;49(7):731-741. doi: 10.1016/j.dld.2017.03.027. Epub 2017 Apr 12.
153. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10
154. Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0
155. Degasperi E, Aghemo A, Colombo M Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017 Aug;21(3):631-643. doi: 10.1016/j.cld.2017.03.015. Review.
156. Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125-133
157. D'Ambrosio R, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P. Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression. Liver Int. 2018 Jan 27. doi: 10.1111/liv.13707
158. Aghemo A, Colombo M. Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle? Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30100-8. doi: 10.1053/j.gastro.2018.01.035
Nome e Cognome: Alessio Michele Goffredo Aghemo
Nascita: 14/2/1975 Milano
Cittadinanza: Italiana
Residenza: Milano
Codice fiscale: GHMLSM75B14F205A
Indirizzo del luogo di lavoro:
Departimento di Scienze Biomediche
Humanitas University
UO Medicina Interna ed Epatologia
Humanitas Research Hospital
Via Manzoni 56, 20089, Rozzano (MI)
E-mail: alessio.aghemo@hunimed.eu
alessio.aghemo@gmail.com
CORSO DEGLI STUDI ED INCARICHI PROFESSIONALI
1994 Maturita' Scientifica, Liceo Gonzaga, Via Vitruvio 41 Milano
2001 Laurea in Medicina e Chirurgia, votazione 110/110 lode, Universita' degli Studi di Milano,
2001-2005 Specializzazione in Gastroenterologia ed Endoscopia digestiva votazione 70/70 lode, Università degli Studi di Milano
2005-2008 Dottorato di Ricerca in Gastroenterologia, Universita' degli Studi di Milano
2006-2007 Borsa di Ricerca, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
2007-oggi Dirigente Medico di I livello, UO di Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano.
2008-oggi Professore a contratto della Scuola di Specializzazione in Gastroenterologia Digestiva ed Endoscopia dell’Università degli Studi di Milano
2008-oggi Docente del corso di Laurea Magistrale in Medicina e Chrirurgia della facoltà di Medicina e Chirurgia dell’Università degli Studi di Milano
2011-2013 Docente del Corso di Laurea in “Tecniche di Radiologia Medica, per immagini e radioterapia” dell’Università degli Studi di Milano
2013 Abilitazione scientifica nazionale a Professore Associato di Gastroenterologia
2014-2017 Indennità Professionale di alta Specializzazione in Epatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano
2017-2021 Professore Associato di Gastroenterologia, Humanitas University, Rozzano Italia
2017-oggi Responsabile UO Medicina generale ed Epatologia, Humanitas Research Hospital, Rozzano Italia
2021-oggi Professore Ordinario di Gastroenterologia, Humanitas University, Rozzano Italia
CONOSCENZE LINGUISTICHE
Inglese Scritto e Parlato: Ottimo
Francese: Scritto Buono, Parlato Ottimo
ATTIVITA’ DIDATTICA E SCIENTIFICA
Attività didattica
Anno Accademico 2007-2008
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Anno Accademico 2008-2009
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Anno Accademico 2009-2010
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Anno Accademico 2010-2011
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Anno Accademico 2011-2012
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Medicina e Chirurgia, corso di Gastroenterologia dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Tecniche di radiologia medica, per immagini e radioterapia, corso di Malattie infettive dell’Università degli Studi di Milano.
Anno Accademico 2012-2013
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Professore a contratto del Corso di laurea in Tecniche di radiologia medica, per immagini e radioterapia, corso di Malattie infettive dell’Università degli Studi di Milano.
Anno Accademico 2014-2015
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Anno Accademico 2015-2016
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Anno Accademico 2016-2017
Professore a contratto della Scuola di Specializzazione in Gastroenterologia ed Endoscopia Digestiva dell’Università degli Studi di Milano.
Tutor per le attività professionalizzanti per gli studenti di corso di Laurea in Medicina e chirurgia dell’Università degli Studi di Milano.
Anno Accademico 2017-2021
Professore Associato di Gastroenterologia presso la Humanitas University
Anno Accademico 2021-oggi
Professore Ordinario di Gastroenterologia presso la Humanitas University
Attività scientifica
Dal 2005 al 2017 ha svolto la sua attività scientifica presso i laboratori della U.O. di Gastroenterologia I della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, di Milano.
E’ stato fino al 2017 responsabile della sezione HCV dei laboratori di ricerca della U.O. Gastroenterologia ed Epatologia
E’ stato visiting fellow presso la Duke University nel 2010, sotto la diezione del Professore Andrew J. Muir.
I principali temi di ricerca sono stati:
1) Ottimizzazione della efficacia e tollerabilità della terapia antivirale contro HCV
2) Impatto dei polimorfismi genetici sulla storia naturale dell’epatite cronica HCV e sull’efficacia terapeutica dei farmaci antivirali
3) Caratterizzazione delle resistenze virali a farmaci anti-HCV ad azione diretta e loro impatto sull’efficacia dei farmaci stessi
Ha partecipato in qualità di esperto alla stesura delle Linee Guida Europee 2013-2014-2015-2016 (EASL) ed Italiane (AISF) sul Trattamento dell’Epatite Cronica C.
E’ componente del gruppo di esperti Europei che sta preparando le linee guida EASL per l’epatite cronica C del 2017.
E’ socio dell’European Association for the Study of the Liver (EASL), dell’ American Association for the Study of the Liver (AASLD), dell’Associazione Italiana Studio Fegato (AISF) e della Società Italiana di Gastroenterologia (SIGE).
E’ stato Associate Editor di Liver International dal 2013 al 2019.
Dal 2019 ad oggi è Co Editor in Chief di Liver International
E’ membro dell’editorial board delle seguenti riviste: Journal of Hepatology, Gut.
È stato Revisore delle seguenti riviste scientifiche internazionali: Hepatology, Gastroenterology, Lancet Infectious diseases, Gut, Journal of Hepatology, Annals of Internal Medicine, Journal of Viral Hepatitis, Lancet Gastroenterology and Hepatology, Liver International, Journal of Medical Virology, BMC Gastroenterology, Clinical Gastroenterology and Hepatology.
E’ autore di 280 pubblicazioni su riviste peer-reviewed (Impact Factor totale >2000, H-Index 45 secondo Scopus, H-Index 50 secondo Google Scholar)
Attività di Cordinamento e Finanziamenti
Dal 2013 al 2016 è stato scientific member del governing board dell’European Association for the Study of the Liver (EASL).
Dal 2016 è member del scientific comitee della associazione Europea di Gastroenterologia (UEG)
É membro della commissione AISF per i farmaci antivirali diretti contro HCV (2012-oggi). Dal 2016 è cordinatore della stessa.
Esperto AIFA/EMEA per la malattie del fegato dal 2008
Membro del Comitato Esecutivo della Rete Regionale HCV, determinata da Regione Lombardia in data 28 Settembre 2015 (determina 7826).
Dal 2016 fino al 2019 è membro del comitato scientifico del Centro Universitario A.M e A. Migliavacca per lo Studio e la Cura delle malatie del fegato dell’Università degli studi di Milano
Vincitore del Progetto Fellowship Program GILEAD Titolo del progetto: Creazione di un punteggio per identificare le persone ad alto rischio di sviluppo di infezione da virus dell’epatite C dopo esposizione professionale per identificare I candidati ideali a profilassi antivirale post-esposizione. Finanziamento 15.000 Euro
Vincitore del Progetto di Ricerca Giovani Ricercatori del Ministero della Salute Bando 2011 come membro del team di ricerca di centro affiliato. Titolo: Effect of Proteasome and VEGF receptor inhibitors on NKG2D ligand expression on hepatocellular carcinoma cells: implications for immunotherapy of liver cancer. Finanziato con 62.000 Euro.
ATTIVITA’ CLINICA ASSISTENZIALE
- Dal 1998 al 2001, ha svolto attività di Medico Interno c/o il reparto di Degenza e l’ambulatorio di epatologia della Unità di Gatroenterologia 1, IRCCS Ospedale Maggiore Policlinico, Milano.
- Dal 2001 al 2005 ha svolto attività clinica ed endoscopica presso le unità di Gatroenterologia I e III della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2006 al 2017 ha svolto attività clinico assistenziale presso la U.O di Gastroenterologia I della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2007 al 2017 è stato Dirigente medico di 1° Livello presso la U.O di Gastroenterologia I della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano
- Nel 2009 è stato Medico Responsabile del Reparto Degenza, UO di Gastroenterologia I, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2009 al 2017 è consulente epatologo della divisione del centro emofilia e trombosi Bianchi Bonomi della Divisione di Medicina Interna, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano.
- Dal 2008 al 2017 è consulente epatologo dell’Ospedale Ortopedico Gaetano Pini di Milano
- Dal 2010 al 2017 è referente per le attività ambulatoriali della U.O di Gastroenterologia ed Epatologia della Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
- Dal 2014 al 2017 ha l’Indennità Professionale di alta Specializzazione (IPS) in Epatologia, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano
- Dal 2017 ad oggi è Capo sezione presso la UO Medicina generale ed Epatologia, Humanitas Research Hospital, Rozzano Italia
ARTICOLI ORIGINALI
1. Viganò M, Visentin S, Aghemo A, Rumi M.G, Ronchi G. Ultrasound features of liver surface nodularity predict severe fibrosis in chronic hepatitis C. Radiology 2005;234(2):641
2. Monti V, Aghemo A, Rumi MG, Donato F, Del Ninno E, Colombo M. Prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C and liver-kidney microsomal antibodies. Antiviral Therapy 2005;10(6):715-720.
3. Rumi M, D’Ambrosio R, Aghemo A. The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology 2006 Apr;44(4):825.
4. Aghemo A, Rumi MG, Soffredini R, D’Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antiviral Therapy 2006; 11 (6): 797-802.
5. Rumi MG, Aghemo A, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Therapy 2007;12(7):1033-40
6. Viganò M, Aghemo A, Iavarone M. The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis. Gastroenterology 2007;133(6):2076.
7. Taliani G, Rucci P, Biliotti E, Cirrincione L, Aghemo A, Alberti A, Almasio PL, Bartolozzi D, Caporaso N, Coppola R, Chiaramonte M, Floreani A, Gaeta GB, Persico M, Secchi G, Versace I, Zacharia S, Mele A. Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. J Viral Hepat. 2007;14(12):875-82.
8. Aghemo A, Rumi MG, Colombo M. Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? J Viral Hepat. 2008;15(6):471
9. Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur J Intern Med. 2008;19(5):370-1.
10. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, Andreone P, Stanzione M, Mazzella G, Saracco G, Del Poggio P, Bruno S; on behalf of Italian Association of the Study of the Liver Disease (AISF). Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. Am J Gastroenterol. 2008;103(8):1966-72.
11. Aghemo A, D’Ambrosio R, Rumi MG, Colombo M. Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C: more questions than answers. Hepatitis Monthly. 2008;8(4):304-309
12. Aghemo A, Colombo M. Cirrhosis Regression in Chronic Hepatitis c: an old tale with a new ending. Gastroenterology. 2009;136(3):1114-6.
13. Aghemo A, Rumi MG, Prati GM, Colombo M. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more? Hepatology. 2009;49(2).
14. Martinelli I, Primignani M, Aghemo A, Reati R, Bucciarelli P, Fabris F, Battaglioli T, Dell'era A, Mannucci PM. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol. 2009 May;50(5):916-22
15. Tripodi A, Chantarangkul V, Primignani M, Dell’Era A, Clerici M, Iannuzzi F, Aghemo A, Cazzaniga M, Salerno F, Mannucci PM. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement INRliver for the calculation of the MELD score. J Hepatol. 2009;51(2):288-95.
16. Aghemo A, Rumi MG, Monico S, Prati GM, D’Ambrosio R, Donato MF, Colombo M. The pattern of peginterferon alfa-2b ribavirin treatment failure in cirrhotics depends on hepatitis C virus genotype. Antivir Ther. 2009;14(4):577-84
17. M Viganò§, A Aghemo§, M Iavarone, MG Rumi, F Agnelli, P Lampertico, MF Donato and M .Colombo. The course of inactive hepatitis B in hepatitis C co-infected patients treated with interferon and ribavirin. Antiviral Therapy 2009 14(6):789-96.
18. Aghemo A, Colombo M. Treatment of nonresponder patients with chronic hepatitis C: to repeat or not to repeat? That is the question. Gastroenterology. 2009 Oct;137(4):1521-4;
19. De Nicola S, Aghemo A, Rumi MG, Colombo M. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C.J Hepatol. 2009 Nov;51(5):964-6.
20. Mancuso ME, Rumi MG, Aghemo A, Santagostino E, Puoti M, Coppola A, Colombo M, Mannucci PM. HCV/HIV co-infection in hemophiliacs: high rates of sustained virological response to pegylated interferon and ribavirin therapy. J Thromb Haemost. 2009;7(12):1997-2005
21. Aghemo A, Rumi MG, Colombo M. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther. 2009 Oct;7(8):925-35
22. Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV Therapy. Viruses 2009, 1(3), 484-509
23. Rumi M, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M. Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology. 2010;138(1):108-15
24. Aghemo A, Colombo M. Peginterferon Alfa-2B Versus Peginterferon Alfa-2A With Ribavirin for the Treatment of Chronic Hepatitis C: The Pursuit of an Ideal. Gastroenterology. 2010;138(1):386-9
25. Aghemo A, Colombo M. Genetic Variation in Interleukin-28B Predicts Hepatitis C Treatment-Induced Viral Clearance in Genotype 1 Patients: The Dawn of a New Era? Gastroenterology. 2010;138(7):2546-9
26. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell'Era A, Iannuzzi F, Aghemo A, Mannucci PM. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology. 2010;52(1):249-55.
27. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2010;7(9):485-94.
28. Aghemo A, Colombo M. Telaprevir for Hepatitis C Retreatment: An Open Door on a Long and Winding Road. Gastroenterology. 2010 Aug 20. [Epub ahead of print]
29. Aghemo A, Rumi MG, De Nicola S, Colombo M. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. Hepatology. 2010;52(3):1170-1.
30. Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, Ronchi G, Biondetti P, Roncalli M, Colombo M. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology. 2010;52(5):1723-30.
31. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32(13):2117-38.
32. Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A, Mannucci PM. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med. 2011 Feb 5.
33. Vezali E, Aghemo A, Colombo M Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther. 2011;11(3):301-13.
34. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53(3):791-9.
35. Aghemo A, Colombo M. A Rapid Point-of-Care Test for the Diagnosis of HCV Infection: Tipping the Balance to Screening Extension Beyond High Risk Populations? Gastroenterology. 2011;140(4):1347-9
36. Aghemo A, Rumi MG, Monico S, Banderali M, Russo A, Ottaviani F, Vigano M, D'Ambrosio R, Colombo M. Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepat Mon. 2011 Nov;11(11):918-24.
37. Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol. 2011 Mar 22. [Epub ahead of print] IF 318
38. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011 Oct;54(4):1127-34. doi: 10.1002/hep.24503.
39. Prati GM, Aghemo A, Rumi MG, D'Ambrosio R, De Nicola S, Donato MF, Degasperi E, Colombo M. Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol. 2012 Feb;56(2):341-7.
40. Aghemo A, Colombo M. Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. J Hepatol. 2012;56(1):276-8.
41. D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'Era A, Lampertico P, Donato MF, De Nicola S, Prati GM, de Franchis R, Colombo M. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16(5):677-84.
42. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012;55(2):336-42.
43. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12(2):193-207.
44. Valenti L, Aghemo A, Stättermayer AF. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol. 2012 May;56(5):1209-10.
45. Degasperi E, Aghemo A. Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:3-6.
46. Rumi M, Aghemo A, Prati GM. Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:37-41.
47. D'Ambrosio R, Aghemo A, Grazia Rumi M, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients. Hepatology. 2012 Jan 23. doi: 10.1002/hep.25606
48. Donato MF, Galmozzi E, Rigamonti C, Aghemo A. Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. J Hepatol. 2012 Jan 28. [Epub ahead of print]
49. Aghemo A, Prati GM, Colombo M. Reply to: "The "pegylated" story continues - Perhaps because both ends (α2a and α2b) are true?" J Hepatol. 2012 Mar 3. [Epub ahead of print]
50. Aghemo A, Colombo M. Interferon-Free Oral Therapy for Hepatitis C: "Faraway, so Close!". Gastroenterology. 2012;142(5):1253-4.
51. Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther. 2012;35(12):1434-42
52. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. Hepatology. 2012 56(5):1681-7
53. Aghemo A.Understanding the Role of PNPLA3 Genetic Variants in Patients with Chronic Hepatitis C Infection. Dig Dis Sci. 2012 Jun 27. [Epub ahead of print] No abstract available.
54. Aghemo A, Lampertico P, Colombo M. Assessing Long-Term Treatment Efficacy in Chronic Hepatitis B and C: Between Evidence and Common Sense. J Hepatol. 2012 Jun 27. [Epub ahead of print]
55. Galmozzi E, Aghemo A, Colombo M. Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin? Med Hypotheses. 2012;79(4):471-3
56. D'Ambrosio R, Aghemo A.Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon. 2012;12(6):361-8
57. D'Ambrosio R, Aghemo A, Colombo M. Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. Biologics. 2012;6:363-70.
58. Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon. 2012;12(6):411-4
59. Aghemo A, Colombo M. Insulin Resistance and Response to Telaprevir Plus Pegylated Interferon and Ribavirin: a Requiem For The Homa Score? Gastroenterology. 2012;143(6):1685-7
60. Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. Dig Liver Dis. 2013;45(1):1-7.
61. Galmozzi E, Aghemo A, Colombo M. Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. Hepatology. 2013 May;57(5):2087.
62. Galmozzi E, De Nicola S, Aghemo A, Colombo M. Is there need for more than one IL28B SNP in Hepatitis C clinical practice? Hepatology 2013. Jan;57(1):416.
63. Iavarone M, Manini MA, Sangiovanni A, Fraquelli M, Forzenigo LV, Di Tommaso L, Aghemo A, Roncalli M, Ronchi G, Colombo M. Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. Dig Liver Dis. 2013;45(1):43-9
64. Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol. 2013 Jan;35(1):111-20
65. Lotta LA, Degasperi E, Aghemo A, Ferrari B, Peyvandi F, Colombo M. Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. Transfus Med. 2013;23(1):66-8.
66. Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P. Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. J Virol Methods. 2013;187(2):271-3.
67. Grassi E, Aghemo A. How to optimize HCV therapy in genotype 2 patients. Liver Int. 2013;33 Suppl 1:35-40.
68. Dell'Osso B, Prati G, Palazzo MC, Rumi MG, Cavallaro F, Aghemo A, Colombo M, Altamura AC. Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. J Interferon Cytokine Res. 2013;33(1):9-14
69. Aghemo A, De Francesco R New horizons in Hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58(1):428-38..
70. Oliviero B, Mele D, Degasperi E, Aghemo A, Cremonesi E, Grazia Rumi M, Tinelli C, Varchetta S, Mantovani S, Colombo M, Mondelli MU. Natural Killer Cell Dynamic Profile Is Associated with Treatment Outcome in Patients with Chronic HCV Infection. J Hepatol. 2013;59(1):38-44
71. D'Ambrosio R, Aghemo A, Fraquelli M, Grazia Rumi M, Francesca Donato M, Paradis V, Bedossa P, Colombo M. The Diagnostic Accuracy of Fibroscan for Cirrhosis is Influenced by Liver Morphometry in HCV Patients with a Sustained Virological Response. J Hepatol. 2013;59(2):251-6
72. Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol. 2013 Mar 7;19(9):1359-71.
73. Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, Grassi E, Colombo M. Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. Biomed Res Int. 2013;2013:580796.
74. Degasperi E, Viganò M, Aghemo A, Lampertico P, Colombo M. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther. 2013;11(5):459-74
75. Aghemo A, Colombo M. Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. Gastroenterology. 2013;145(1):247-9.
76. Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013 Jul 3. doi: 10.1038/ki.2013.264.
77. Aghemo A, Colombo M. Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut. 2013 Aug 6. doi: 10.1136/gutjnl-2013-305115
78. Aghemo A, Lampertico P. Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. Aliment Pharmacol Ther. 2013 Sep;38(5):553-4
79. De Nicola S, Aghemo A, Campise MR, D'Ambrosio R, Rumi MG, Messa P, Colombo M. Telaprevir in a patient with chronic hepatitis C and Cryoglobulinemic Glomerulonephritis. Antivir Ther. 2013 Sep 6. doi: 10.3851/IMP2684.
80. Dell'Era A, Iannuzzi F, Fabris FM, Fontana P, Reati R, Grillo P, Aghemo A, de Franchis R, Primignani M. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig Liver Dis. 2014 Feb;46(2):152-6
81. Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2014 Jan;46(1):18-24.
82. Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D'Ambrosio R, Muir AJ, Colombo M. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat. 2013 Dec;20(12):858-66
83. Fabrizi F, Aghemo A, Moroni G, Passerini P, D'Ambrosio R, Martin P, Messa P. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review). Dig Dis Sci. 2014 Mar;59(3):691-5.
84. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420
85. Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res. 2013;37(6):588-601.
86. Fraquelli M, Giunta M, Pozzi R, Rigamonti C, Della Valle S, Massironi S, Conti CB, Aghemo A, Ronchi G, Iurlo A, Primignani M, Conte D, Colombo M. Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis. J Viral Hepat. 2014 Feb;21(2):90-8
87. Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol. 2014 Jan 11. pii: S0168-8278(14)00013-0. doi: 10.1016/j.jhep.2014.01.002
88. Galmozzi E, Aghemo A. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. J Clin Virol. 2014 Apr;59(4):274-5. doi: 10.1016/j.jcv.2014.01.006.
89. Mancuso ME, Linari S, Aghemo A, Bartolozzi D, Santagostino E, Rumi MG, Fognani E, Fasulo MR, Gragnani L, Bruno R, Morfini M, Zignego AL, Colombo M. Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. Thromb Haemost. 2014 Feb 13;111(6).
90. Degasperi E, Valenti L, Aghemo A, De Francesco R, Rumi M, Soffredini R, Donnici L, Cheroni C, Fargion S, Zanoni V, Orsi E, Colombo M. Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients. Antivir Ther. 2014 Feb 12. doi: 10.3851/IMP2743
91. Fabrizi F, Aghemo A, Fogazzi GB, Moroni G, Passerini P, D'Ambrosio R, Messa P. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38(1):52-60. doi: 10.1159/000355753
92. Aghemo A, Colombo M. Hepatitis C genotype 3: a tough match for interferon-free regimens. Gastroenterology. 2014 Apr;146(4):1125-7
93. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014 Feb;60(2):392-420
94. De Nicola S, Aghemo A. Second wave Anti-HCV Protease Inhibitors: Too little too late? Liver Int. 2014 Mar 20. doi: 10.1111/liv.12543
95. Galmozzi E, Facchetti F, Perbellini R, Aghemo A. High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. Clin Microbiol Infect. 2014 Apr 11. doi: 10.1111/1469-0691.12637. [Epub ahead of print]
96. Ronzoni L, Aghemo A, Rumi MG, Prati G, Colancecco A, Porretti L, Monico S, Colombo M, Cappellini MD. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat. 2014 Jun;21(6):416-23
97. Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M. Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. PLoS One. 2014 Apr 23;9(4):e95881.
98. D'Ambrosio R, Aghemo A, De Francesco R, Rumi MG, Galmozzi E, De Nicola S, Cheroni C, Clark PJ, Ronchi G, Lampertico P, Colombo M. The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci. 2014 Apr 25;15(5):7213-24
99. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med. 2014 Apr 29;6:25-33
100. Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M. An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. Dig Liver Dis. 2014 Sep;46(9):818-25.
101. Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, Torresani E, Ronchi M, Garlaschi MC, Ramondetta M, Colombo M. Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients. J Viral Hepat. 2014 Jul 14. doi: 10.1111/jvh.12281
102. Donato MF, Monico S, Malinverno F, Aghemo A, Maggioni M, Reggiani P, Colombo M. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int. 2014 Jul 29. doi: 10.1111/liv.12646.
103. De Nicola S, Dongiovanni P, Aghemo A, Cheroni C, D'Ambrosio R, Pedrazzini M, Marabita F, Donnici L, Maggioni M, Fargion S, Colombo M, De Francesco R, Valenti L Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS One. 2014 Aug 29;9(8):e106022
104. Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut. 2014 Sep 5. pii: gutjnl-2014-307958
105. Fabrizi F, D'Ambrosio R, Pallotti F, Berardinelli L, Messa P, Martin P, Aghemo A. Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study. Int J Artif Organs. 2014;37(11):803-8.
106. Aghemo A, Donato MF.Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148(1):13-6.
107. D'Ambrosio R, Aghemo A, Colombo M. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opin Drug Saf. 2015;14(3):473-84
108. Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D'Ambrosio R, Maggioni M, De Francesco R, Fargion S, Berg T, Stickel F, Hampe J, Romeo S, Colombo M, Valenti L. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015 Jul;62(1):111-7. doi: 10.1002/hep.27811. Epub 2015 May 6
109. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21..
110. Romeo S, Aghemo A, Berg T, Stickel F, Valenti L. Reply. Hepatology. 2015 May 16. doi: 10.1002/hep.27901.
111. Manini MA, Sangiovanni A, Martinetti L, Viganò D, La Mura V, Aghemo A, Iavarone M, Crespi S, Nicolini A, Colombo M. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl. 2015 Oct;21(10):1259-69. doi: 10.1002/lt.24196.
112. Aghemo A, Colombo M. Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era? Gastroenterology. 2015 Aug;149(2):500-1. doi: 10.1053/j.gastro.2015.06.035. Epub 2015 Jun 27. No abstract available
113. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.
114. Bruno R, Aghemo A. Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00549-8. doi: 10.1016/j.jhep.2015.05.034. [Epub ahead of print] No abstract available.
115. Grancini V, Trombetta M, Lunati ME, Zimbalatti D, Boselli ML, Gatti S, Donato MF, Resi V, D'Ambrosio R, Aghemo A, Pugliese G, Bonadonna RC, Orsi E. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. J Hepatol. 2015 Aug 20. pii: S0168-8278(15)00553-X. doi: 10.1016/j.jhep.2015.08.011.
116. Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, Sarrazin C. Should HCV-infected patients with debilitating fatigue be prioritized for treatment with interferon-free regimens? J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00619-4. doi: 10.1016/j.jhep.2015.09.004. [Epub ahead of print] No abstract available.
117. Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, Abrignani S, Neddermann P, De Francesco R. Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. PLoS One. 2015 Sep 25;10(9):e0138546. doi: 10.1371/journal.pone.0138546. eCollection 2015.
118. Premoli C, Aghemo A. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants. Minerva Gastroenterol Dietol. 2016 Mar;62(1):76-87.
119. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015 Nov;64(11):1824-33.
120. Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden - volume 3 (editorial). J Viral Hepat. 2015 Dec;22 Suppl 4:1-3
121. Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V, Fischer J, Berg T, Aghemo A, Cheroni C, De Francesco R, Fargion S, Colombo M, Datz C, Stickel F, Valenti L, Romeo S. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology. 2016 Feb;63(2):418-27
122. Paolini D, Lunghi G, Aghemo A, Dionisi M, Colombo M, Torresani E. Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or Triple) Therapy of Hcv Genotype 1 Infection. Value Health. 2015 Nov;18(7):A587
123. Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2015;16(17):2679-88
124. Varchetta S, Mele D, Lombardi A, Oliviero B, Mantovani S, Tinelli C, Spreafico M, Prati D, Ludovisi S, Ferraioli G, Filice C, Aghemo A, Lampertico P, Facchetti F, Bernuzzi F, Invernizzi P, Mondelli MU. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut. 2015 Dec 16. pii: gutjnl-2015-310327. doi: 10.1136/gutjnl-2015-310327
125. Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50
126. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. Int J Drug Policy. 2015 Nov 28. pii: S0955-3959(15)00352-7. doi: 10.1016/j.drugpo.2015.11.010
127. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; l’International Network on Hepatitis among Substance Users (Réseau international sur l’hépatite chez les consommateurs de drogues). Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. Int J Drug Policy. 2015 Nov 28. pii: S0955-3959(15)00351-5. doi: 10.1016/j.drugpo.2015.11.009
128. Aghemo A, Colombo M. No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered? Gastroenterology. 2016 May;150(5):1241-3. doi: 10.1053/j.gastro.2016.03.025
129. Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D'Ambrosio R, Soffredini R, Perbellini R, Lunghi G, Colombo M. Quantification of Core Antigen Monitors Efficacy of Direct-Acting Antiviral Agents in Patients With Chronic Hcv Infection. Clin Gastroenterol Hepatol. 2016 Apr 1. pii: S1542-3565(16)30010-6. doi: 10.1016/j.cgh.2016.03.035. [Epub ahead of print]
130. Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075-1. doi: 10.1016/j.jhep.2016.01.034
131. De Nicola S, Aghemo A. The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. Liver Int. 2016 Jun;36(6):791-3.
132. D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One. 2016 Jun 15;11(6):e0155967. doi: 10.1371/journal.pone.0155967. eCollection 2016.
133. Fraquelli M, Baccarin A, Casazza G, Conti CB, Giunta M, Massironi S, Invernizzi F, Donato MF, Maggioni M, Aghemo A, Conte D, Colombo M. Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease. Aliment Pharmacol Ther. 2016 Jun 30. doi: 10.1111/apt.13711
134. Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. From current status to optimization of HCV treatment: Recommendations from an expert panel. Dig Liver Dis. 2016 Jun 15. pii: S1590-8658(16)30463-7. doi: 10.1016/j.dld.2016.06.004
135. Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia S, Cacciola I, Burroughs AK, Manini MA, La Mura V, Angeli P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, Arghittu M; AISF Investigators. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int. 2016 Jul 1. doi: 10.1111/liv.13195.
136. D'Ambrosio R, Aghemo A, Rossetti V, Carrinola R, Colombo M. Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver Int. 2016 Jul 18. doi: 10.1111/liv.13203
137. Aghemo A, De Nicola S. Chronic hepatitis C: standard of care and perspective. Recenti Prog Med. 2016;107(7):349-54
138. Aghemo A, Buti M. Hepatitis C Therapy: Game Over! Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131-9. doi: 10.1053/j.gastro.2016.09.034
139. Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1373-1383.
140. Colli A, Fraquelli M, Prati D, Riva A, Berzuini A, Conte D, Aghemo A, Colombo M, Casazza G. Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. PLoS One. 2016 Oct 10;11(10):e0164452. doi: 10.1371/journal.pone.0164452.
141. Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, Massetto B, Brainard DM, McHutchison JG, Bourlière M, Peck-Radosavljevic M, Manns M, Pol S. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Ann Intern Med. 2016 Nov 15. doi: 10.7326/M16-1205
142. Tripodi A, D'Ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int. 2017 Jan 27. doi: 10.1111/liv.13374
143. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Jan 20. doi: 10.1111/liv.13327.
144. Aghemo A, Bruno R, Colombo M, Medagli M, Puoti M, Rizzardini G, Fagiuoli S; Lombardia Hepatitis Network. Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):17-19.
145. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20
146. Tripodi A, D'Ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int. 2017 Sep;37(9):1295-1303. doi: 10.1111/liv.13374. Epub 2017 Feb 23
147. Aghemo A, Colombo M. Response-Guided Duration of Direct Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future? Gastroenterology. 2017 Apr;152(5):1238-1239. doi: 10.1053/j.gastro.2017.02.022. Epub 2017 Feb 28. No abstract available.
148. Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K, Piratvisuth T, Shah S, Shiffman ML, Tacke F, Tan SS, Tanwandee T, Win KM, Yurdaydin C. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62. doi: 10.1016/S2468-1253(16)30080-2. Epub 2016 Dec 10. Review
149. Invernizzi F, Aghemo A. Treatment of chronic hepatitis C: can complexity pave the way towards elimination? Lancet Gastroenterol Hepatol. 2017 Jul;2(7):465-466. doi: 10.1016/S2468-1253(17)30085-7. Epub 2017 Apr 14. No abstract available
150. Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, Cabibbo G, Rossi S, Calvaruso V, Aghemo A, Giacomelli L, Craxì A, Colombo M, Maisonneuve P. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int. 2017 Apr 18. doi: 10.1111/liv.13452. [Epub ahead of print]
151. D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017 Jun;24:31-37. doi: 10.1016/j.coviro.2017.03.017. Epub 2017 Apr 15. Review.
152. Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis. 2017 Jul;49(7):731-741. doi: 10.1016/j.dld.2017.03.027. Epub 2017 Apr 12.
153. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10
154. Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0
155. Degasperi E, Aghemo A, Colombo M Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017 Aug;21(3):631-643. doi: 10.1016/j.cld.2017.03.015. Review.
156. Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125-133
157. D'Ambrosio R, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P. Persistence of hepatocellular carcinoma risk in hepatitis c patients with a response to ifn and cirrhosis regression. Liver Int. 2018 Jan 27. doi: 10.1111/liv.13707
158. Aghemo A, Colombo M. Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle? Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30100-8. doi: 10.1053/j.gastro.2018.01.035